A Phase 2 Trial of Tobevibart plus Elebsiran in Hepatitis D
In this phase 2 trial, tobevibart plus elebsiran as well as tobevibart monotherapy decreased HDV RNA and ALT levels through week 48. Treatment with tobevibart plus elebsiran was associated with a high incidence of undetectable HDV RNA and of a decrease in the HBsAg level. (Funded by Vir Biotechnology; ClinicalTrials.gov number, NCT05461170.).
Authors
- Tarik Asselah (ORCID: https://orcid.org/0000-0002-0024-0595)
- Grégory Camus (ORCID: https://orcid.org/0000-0002-0018-6234)
- Brianna L. Bullard (ORCID: https://orcid.org/0000-0002-6702-0079)
- Diogo Pereira dos Santos
- Sophia Chow
- Carey Hwang
- Alina Jucov
- Adrian Streinu‐Cercel (ORCID: https://orcid.org/0000-0001-6382-5067)
- Todd Correll
- Michael A. Chattergoon (ORCID: https://orcid.org/0000-0002-2220-1116)
- Kosh Agarwal (ORCID: https://orcid.org/0000-0002-4754-828X)
- Heiner H. Wedemeyer (ORCID: https://orcid.org/0000-0003-2906-0480)
- Edward Gane (ORCID: https://orcid.org/0000-0003-4086-7955)
- Cara Pilowa
- Pietro Lampertico (ORCID: https://orcid.org/0000-0002-1026-7476)
- Yimeng Lu
- Patrick T. Kennedy
Institutions
- Auckland Institute of Studies (NZ)
- Inserm (FR)
- Carol Davila University of Medicine and Pharmacy (RO)
- Queen Mary University of London (GB)
- University of Milan (IT)
- Hôpital Beaujon (FR)
- Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico (IT)
- Foundation for Liver Research (GB)
- Medizinische Hochschule Hannover (DE)
- Ospedale Maggiore (IT)
- Vir Biotechnology (Switzerland) (CH)
- Assistance Publique – Hôpitaux de Paris (FR)
- Nicolae Testemițanu State University of Medicine and Pharmacy (MD)
- Orano (United States) (US)
Publication Details
- Journal
- New England Journal of Medicine
- Published
- 2025-11-09
- DOI
- https://doi.org/10.1056/nejmoa2508827
- Citations
- 6
- Primary Topic
- Hepatitis B Virus Studies
- Type
- article
- Field-Weighted Citation Impact
- 8.13